Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Second-quarter sales rose to $2.6 billion, up 4% year-over-year on a reported basis.
  • Reported diluted EPS was $0.35; core diluted EPS came in at $0.76.
  • Announced STAAR acquisition and launched Tryptyr in the U.S. this quarter.

Alcon reported second-quarter 2025 results with net sales of approximately $2.6 billion, a 4% increase on a reported basis and 3% in constant currency versus the prior-year quarter. The company posted diluted earnings per share of $0.35 and core diluted EPS of $0.76 for the quarter. Cash generation remained meaningful in the first half of 2025, with $889 million from operations and $681 million of free cash flow, and the company returned about $287 million to shareholders during the period.

Beyond headline financials, Alcon highlighted recent product activity and a near-term strategic acquisition. The company launched Tryptyr (acoltremon ophthalmic) in the U.S., positioning the product as a new treatment option for dry eye disease following regulatory approval and commercialization efforts. In a separate development, Alcon announced an agreement to acquire STAAR Surgical — a move that adds the Implantable Collamer Lens (EVO) to Alcon’s portfolio and expands its footprint in myopia correction. The STAAR transaction terms disclosed by Alcon value the deal at roughly USD 1.5 billion, with an offered price of USD 28.00 per share in cash.

Management framed these items as part of a broader commercial and portfolio strategy: new product introductions and targeted M&A that extend treatment options across refractive and therapeutic eye care categories. That narrative was accompanied by commentary on market conditions, with reference to softer surgical activity in the first half of the year and early demand for recently launched products. Investors and analysts will likely weigh the revenue contribution and margin impact from launches, the near-term effects of integration and acquisition costs, and the durability of cash generation reported year-to-date.

From an analytical perspective, the quarter mixes solid top-line growth with a decline in reported diluted EPS versus the prior year, reflecting operating variances and discrete items cited by the company. The announced STAAR purchase and Tryptyr commercial rollout are the most material strategic items for the remainder of 2025; market participants should monitor regulatory clearances, integration commentary, and upcoming quarterly disclosures for updated guidance and financial detail.